ASX Share rice
Mon 17 May 2021 - 05:11:am (Sydney)

ANP Share Price

ANTISENSE THERAPEUTICS LIMITEDANPPharmaceuticals, Biotechnology & Life Sciences

ANP Company Information


Antisense Therapeutics Limited




Drug Manufacturers-Specialty & Generic

GIC Industry:


GIC Sub Industry:



14 Wallace Avenue Toorak VIC Australia 3142


61 3 9827 8999

CEO, MD & Director:

Mr. Mark Diamond B.Sc., M.B.A., BSc, MBA, MAICD

CFO & Joint Company Sec.:

Mr. Phillip Allen Hains

Joint Company Sec.:

Ms. Alicia Mellors

Company Overview:

Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d that has completed Phase IIa for the treatment of multiple sclerosis, Duchennes Muscular Dystrophy, multiple sclerosis, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.

ANP Share Price Information

Shares Issued:


Market Capitalisation:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


ANP CashFlow Statement

CashFlow Date:




Change To Liabilities:


Total Cashflow From Investing Activities:


Net Borrowings:


Net Income:


Total Cash From Operating Activities:




Change To Account Receivables:


Sale Purchase Of Stock:


Capital Expenditures:


ANP Income Statement

Income Date:


Income Before Tax:


Net Income:


Operating Income:


Total Revenue:


ANP Balance Sheet

Balance Sheet Date:


Total Liabilities:


Total Stockholder Equity:


Other Current Liabilities:


Total Assets:


Common Stock:


Other Current Assets:


Retained Earnings:




Total Current Liabilities:


Property - Plant & Equipment:


Net Tangible Assets:


Total Current Assets:


Net Receivables:


Short-Term Investments:


Accounts Payable:


Short-Term Investments:


Non Current Liabilities Total:


ANP Share Price History

ANP News

26 Nov, 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
11 Jun, 2020
Antisense Therapeutics (ASX:ANP | US OTC:ATHJY), an Australian biopharmaceutical company developing and commercializing antisense pharmaceuticals for unmet need in rare diseases announces a virtual poster presentation on the Muscular Dystrophy Association (MDA) Virtual 2020 Conference website.
28 May, 2020
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
21 May, 2020
Antisense Therapeutics ("ANP" or the "Company" ASX:ANP | US OTC:ATHJY) is pleased to advise that the Phase II clinical trial of ANP’s immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) has met its primary endpoint confirming the safety and tolerability of ATL1102 for advancement into a potentially pivotal Phase IIb clinical trial.